News

Novo Nordisk CEO to step down as obesity drug competition intensifies
Novo Nordisk CEO Lars Jørgensen to step down amid increasing pressure from obesity drug competition and recent share price ...
Novo Nordisk CEO steps down in surprise move as 'market challenges' weigh on obesity drugmaker
"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...
Obesity drug maker Novo Nordisk's CEO to step down amid market struggle
Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down following a plunge in the company's share price ...
Moneyweb1h
Novo ousts CEO Jorgensen after Lilly competition hits shares
The Danish company said Jorgensen is leaving by mutual agreement with the board, though he’ll continue as chief 'for a period ...
Devdiscourse2h
Leadership Shift: Novo Nordisk CEO Jorgensen Steps Down Amid Market Struggles
Novo Nordisk CEO Lars Fruergaard Jorgensen will step down as the company faces challenges in the obesity drug market, which ...
Ozempic maker Novo replaces CEO after share price fall
Jorgensen became CEO in January 2017 and the company’s market capitalization has more than tripled during his tenure. Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, but ...
Fierce Biotech2d
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...
Money Morning1d
Eli Lilly (LLY): Should You Buy or Sell After Drug Price Order?
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...